All In Biotech

Drug Trial Radar · NCT04000529

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

A Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

122

Actual

Start

Jul 30, 2019

Primary completion

Jan 15, 2024

Study completion Jan 15, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 27, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors. These two treatment arms enrolled subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity. The study treatment was administered until the subject experienced unacceptable toxicity, progressive disease, and/or had treatment discontinued at the discretion of the Investigator or the subject, or due to withdrawal of consent.

Conditions

  • Non-small Cell Lung Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Esophageal SCC
  • Gastrointestinal Stromal Tumors
  • Colorectal Cancer

Interventions

  • TNO155Drug

    Capsule

  • SpartalizumabDrug

    Concentrate for solution for infusion

  • RibociclibDrug

    Capsule and tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLT incidenceTime frame: 1 year
  2. AE and SAE incidenceTime frame: 3 years
  3. Dose interruptions, reductions and dose intensity, by treatmentTime frame: 3 years

Locations

10 sites in 9 countries. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Novartis Investigative Site

    Westmead, New South Wales, Australia

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Chengdu, Sichuan, China

  • Novartis Investigative Site

    Cologne, Germany

  • Novartis Investigative Site

    Hong Kong, Hong Kong

  • Novartis Investigative Site

    Chuo Ku, Tokyo, Japan

  • Novartis Investigative Site

    Singapore, Singapore

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    Valencia, Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.